Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever

Psychoneuroendocrinology

Volumn 34, Issue 1, 2009, Pages 118-128

  Kluge, Michael ^a   Schuld, Andreas ^b   Schacht, Alexander ^c   Himmerich, Hubertus ^a,d   Dalal, Mira A ^a   Wehmeier, Peter M ^c   Hinze Selch, Dunja ^e   Kraus, Thomas ^f   Dittmann, Ralf W ^c,g   Pollmächer, Thomas ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b KLINIKUM INGOLSTADT   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f Frankenalb Klinik Engelthal   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Body mass index (BMI); Interleukin; Leptin; Second generation antipsychotics; Tumor necrosis factor (TNF)

Indexed keywords

CLOZAPINE; INTERLEUKIN 6; LEPTIN; OLANZAPINE; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SKINFOLD THICKNESS; TYMPANIC TEMPERATURE; WAIST HIP RATIO; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CLOZAPINE; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; FEVER; HUMANS; LEPTIN; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 57649183937     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.08.016     Document Type: Article

References (74)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
2. Alvir J.M., Lieberman J.A., Safferman A.Z., Schwimmer J.L., and Schaaf J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329 (1993) 162-167
3. Amaral M.E., Barbuio R., Milanski M., Romanatto T., Barbosa H.C., Nadruz W., Bertolo M.B., Boschero A.C., Saad M.J., Franchini K.G., and Velloso L.A. Tumor necrosis factor-alpha activates signal transduction in hypothalamus and modulates the expression of pro-inflammatory proteins and orexigenic/anorexigenic neurotransmitters. J. Neurochem. 98 (2006) 203-212
4. Argiles J.M., Lopez-Soriano J., Busquets S., and Lopez-Soriano F.J. Journey from cachexia to obesity by TNF. FASEB J. 11 (1997) 743-751
5. Baptista T., Sandia I., Lacruz A., Rangel N., de M.S., Beaulieu S., Contreras Q., Galeazzi T., and Vargas D. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int. Clin. Psychopharmacol. 22 (2007) 69-76
6. Baptista T., Zarate J., Joober R., Colasante C., Beaulieu S., Paez X., and Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr. Drug Targets 5 (2004) 279-299
7. Basile V.S., Masellis M., McIntyre R.S., Meltzer H.Y., Lieberman J.A., and Kennedy J.L. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatry 62 Suppl. 23 (2001) 45-66
8. Bastard J.P., Jardel C., Bruckert E., Blondy P., Capeau J., Laville M., Vidal H., and Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 85 (2000) 3338-3342
9. Blum A., and Mauruschat W. Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin. Pharmakopsychiatrie 5 (1972) 155-169
10. Blum W.F., Englaro P., Hanitsch S., Juul A., Hertel N.T., Muller J., Skakkebaek N.E., Heiman M.L., Birkett M., Attanasio A.M., Kiess W., and Rascher W. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J. Clin. Endocrinol. Metab. 82 (1997) 2904-2910
11. Brömel T., Blum W.F., Ziegler A., Schulz E., Bender M., Fleischhaker C., Remschmidt H., Krieg J.C., and Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol. Psychiatry 3 (1998) 76-80
12. Bruun J.M., Pedersen S.B., Kristensen K., and Richelsen B. Opposite regulation of interleukin-8 and tumor necrosis factor-alpha by weight loss. Obes. Res. 10 (2002) 499-506
13. Bruun J.M., Verdich C., Toubro S., Astrup A., and Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur. J. Endocrinol. 148 (2003) 535-542
14. Bulló M., Garcia-Lorda P., and Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes. Eur. J. Endocrinol. 146 (2002) 325-331
15. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
16. Cerami A., Ikeda Y., Le T.N., Hotez P.J., and Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol. Lett. 11 (1985) 173-177
17. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., and Bauer T.L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334 (1996) 292-295
18. Conti B., Tabarean I., Andrei C., and Bartfai T. Cytokines and fever. Front. Biosci. 9 (2004) 1433-1449
19. Dandona P., Weinstock R., Thusu K., bdel-Rahman E., Aljada A., and Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 83 (1998) 2907-2910
20. Erken E., Gunesacar R., Ozbek S., and Konca K. Serum soluble interleukin-2 receptor levels in familial Mediterranean fever. Ann. Rheum. Dis. 55 (1996) 852-855
21. Finck B.N., and Johnson R.W. Tumor necrosis factor (TNF)-alpha induces leptin production through the p55 TNF receptor. Am. J. Physiol Regul. Integr. Comp. Physiol. 278 (2000) R537-R543
22. Gill T., Chittleborough C., Taylor A., Ruffin R., Wilson D., and Phillips P. Body mass index, waist hip ratio, and waist circumference: which measure to classify obesity?. Soz. Praventivmed. 48 (2003) 191-200
23. Hägg S., Söderberg S., Ahrén B., Olsson T., and Mjörndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J. Clin. Psychiatry 62 (2001) 843-848
24. Harvey J., and Ashford M.L. Leptin in the CNS: much more than a satiety signal. Neuropharmacology 44 (2003) 845-854
25. Hauner H., Bender M., Haastert B., and Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int. J. Obes. Relat. Metab. Disord. 22 (1998) 1239-1243
26. Hebebrand J., Blum W.F., Barth N., Coners H., Englaro P., Juul A., Ziegler A., Warnke A., Rascher W., and Remschmidt H. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration. Mol. Psychiatry 2 (1997) 330-334
27. Himmerich H., Binder E.B., Kunzel H.E., Schuld A., Lucae S., Uhr M., Pollmächer T., Holsboer F., and Ising M. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol. Psychiatry 60 (2006) 882-888
28. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., Gedrich K., and Pollmächer T. TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur. Cytokine Netw. 17 (2006) 196-201
29. Himmerich H., Koethe D., Schuld A., Yassouridis A., and Pollmächer T. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology (Berl.) 179 (2005) 447-451
30. Himmerich H., Schuld A., Haack M., Kaufmann C., and Pollmächer T. Early prediction of changes in weight during six weeks of treatment with antidepressants. J. Psychiatr. Res. 38 (2004) 485-489
31. Hinze-Selch D., Deuschle M., Weber B., Heuser I., and Pollmächer T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl.) 149 (2000) 163-169
32. Hinze-Selch D., Schuld A., Kraus T., Kuhn M., Uhr M., Haack M., and Pollmächer T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 23 (2000) 13-19
33. Isidori A.M., Strollo F., More M., Caprio M., Aversa A., Moretti C., Frajese G., Riondino G., and Fabbri A. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J. Clin. Endocrinol. Metab. 85 (2000) 1954-1962
34. Jeong S.H., Ahn Y.M., Koo Y.J., Kang U.G., and Kim Y.S. The characteristics of clozapine-induced fever. Schizophr. Res. 56 (2002) 191-193
35. Kluge M., Schuld A., Himmerich H., Dalal M., Schacht A., Wehmeier P.M., Hinze-Selch D., Kraus T., Dittmann R.W., and Pollmächer T. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J. Clin. Psychopharmacol. 27 (2007) 662-666
36. Kluger M.J. Fever: role of pyrogens and cryogens. Physiol. Rev. 71 (1991) 93-127
37. Kras K.M., Hausman D.B., and Martin R.J. Tumor necrosis factor-alpha stimulates cell proliferation in adipose tissue-derived stromal-vascular cell culture: promotion of adipose tissue expansion by paracrine growth factors. Obes. Res. 8 (2000) 186-193
38. Kraus T., Haack M., Schuld A., Hinze-Selch D., Koethe D., and Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35 (2002) 220-225
39. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kühn M., Uhr M., and Pollmächer T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry 156 (1999) 312-314
40. Lipkovich I., Citrome L., Perlis R., Deberdt W., Houston J.P., Ahl J., and Hardy T. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J. Clin. Psychopharmacol. 26 (2006) 316-320
41. Lord G.M. Leptin as a proinflammatory cytokine. Contrib. Nephrol. 151 (2006) 151-164
42. Maes M., Bosmans E., Kenis G., de J.R., Smith R.S., and Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 26 (1997) 221-225
43. Maes M., Meltzer H.Y., and Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89 (1994) 346-351
44. Mansueto S., D'Ancona F.P., Colletti P., Graceffa R., La S.F., Pecoraro V., Gambino G., Grillo G., Vitale G., Richiusa P., D'Agostino P., and Cillari E. Alteration of interleukin-2 (IL-2) and soluble IL-2 receptor secretion in the sera and urine of patients with rickettsial boutonneuse fever. J. Infect. Dis. 175 (1997) 142-145
45. Martinez J.A., Velasco J.J., and Urbistondo M.D. Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalized psychiatric patients. J. Am. Coll. Nutr. 13 (1994) 192-197
46. Masaki T., and Yoshimatsu H. The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol. Sci. 27 (2006) 279-284
47. McIntyre R.S., Mancini D.A., Basile V.S., Srinivasan J., and Kennedy S.H. Antipsychotic-induced weight gain: bipolar disorder and leptin. J. Clin. Psychopharmacol. 23 (2003) 323-327
48. Megnien J.L., Denarie N., Cocaul M., Simon A., and Levenson J. Predictive value of waist-to-hip ratio on cardiovascular risk events. Int. J. Obes. Relat. Metab. Disord. 23 (1999) 90-97
49. Melkersson K.I., Hulting A.L., and Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry 61 (2000) 742-749
50. Minet-Ringuet J., Even P.C., Valet P., Carpene C., Visentin V., Prevot D., Daviaud D., Quignard-Boulange A., Tome D., and de Beaurepaire R. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol. Psychiatry 12 (2007) 562-571
51. Monteleone P., Fabrazzo M., Tortorella A., La P.S., and Maj M. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J. Clin. Psychopharmacol. 22 (2002) 424-426
52. Monti V., Carlson J.J., Hunt S.C., and Adams T.D. Relationship of ghrelin and leptin hormones with body mass index and waist circumference in a random sample of adults. J. Am. Diet. Assoc. 106 (2006) 822-828
53. Morton G.J., Cummings D.E., Baskin D.G., Barsh G.S., and Schwartz M.W. Central nervous system control of food intake and body weight. Nature 443 (2006) 289-295
54. Otero M., Lago R., Lago F., Casanueva F.F., Dieguez C., Gomez-Reino J.J., and Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 579 (2005) 295-301
55. Pisciotta A.V., and Konings S.A. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. J. Clin. Psychiatry 55 Suppl. B (1994) 143-148
56. Pollmächer T., Hinze-Selch D., Fenzel T., Kraus T., Schuld A., and Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am. J. Psychiatry 154 (1997) 1763-1765
57. Pollmächer T., Hinze-Selch D., and Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16 (1996) 403-409
58. Pollmächer T., Hinze-Selch D., Mullington J., and Holsboer F. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch. Gen. Psychiatry 52 (1995) 877-878
59. Poyurovsky M., Pashinian A., Levi A., Weizman R., and Weizman A. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int. Clin. Psychopharmacol. 20 (2005) 101-103
60. Schuld A., Kraus T., Haack M., Hinze-Selch D., Kuhn M., and Pollmächer T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr. Res. 43 (2000) 164-166
61. Seidell J.C., Perusse L., Despres J.P., and Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am. J. Clin. Nutr. 74 (2001) 315-321
62. Sievenpiper J.L., Jenkins D.J., Josse R.G., Leiter L.A., and Vuksan V. Simple skinfold-thickness measurements complement conventional anthropometric assessments in predicting glucose tolerance. Am. J. Clin. Nutr. 73 (2001) 567-573
63. Simons P.J., van den Pangaart P.S., van Roomen C.P., Aerts J.M., and Boon L. Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: evidence that tumor necrosis factor-alpha- and interleukin-1beta-treated human preadipocytes are potent leptin producers. Cytokine 32 (2005) 94-103
64. Su J.A., Wu C.H., and Tsang H.Y. Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report. Gen. Hosp. Psychiatry 29 (2007) 75-77
65. Tham J.C., and Dickson R.A. Clozapine-induced fevers and 1-year clozapine discontinuation rate. J. Clin. Psychiatry 63 (2002) 880-884
66. Tollefson G.D., Birkett M.A., Kiesler G.M., and Wood A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 49 (2001) 52-63
67. Tolosa-Vilella C., Ruiz-Ripoll A., Mari-Alfonso B., and Naval-Sendra E. Olanzapine-induced agranulocytosis: a case report and review of the literature. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 411-414
68. Turbay D., Lieberman J., Alper C.A., Delgado J.C., Corzo D., Yunis J.J., and Yunis E.J. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 89 (1997) 4167-4174
69. van Dielen F.M., van't Veer C., Buurman W.A., and Greve J.W. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J. Clin. Endocrinol. Metab. 87 (2002) 1708-1716
70. Wehmeier P.M., Gebhardt S., Schmidtke J., Remschmidt H., Hebebrand J., and Theisen F.M. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res. 133 (2005) 273-276
71. Wei M., Stern M.P., and Haffner S.M. Serum leptin levels in Mexican Americans and non-Hispanic whites: association with body mass index and cigarette smoking. Ann. Epidemiol. 7 (1997) 81-86
72. Yoshimatsu H. The neuronal histamine H(1) and pro-opiomelanocortin-melanocortin 4 receptors: independent regulation of food intake and energy expenditure. Peptides 27 (2006) 326-332
73. Ziccardi P., Nappo F., Giugliano G., Esposito K., Marfella R., Cioffi M., D'Andrea F., Molinari A.M., and Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105 (2002) 804-809
74. Zimmermann U., Kraus T., Himmerich H., Schuld A., and Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J. Psychiatr. Res. 37 (2003) 193-220